Grufity logoGrufity logo

DNA

1.99USD+0.01(+0.51%)Market Closed

Ginkgo Bioworks Holdings, Inc.

Market Summary

USD1.99+0.01Market Closed
0.51%

DNA Alerts

DNA Stock Price

RSI Chart

Valuation

Market Cap

4.4B

Price/Earnings

-1.47

Price/Sales

8.09

Price/Cashflow

-15.03

MarketCap/EBT

-1.47

Price/Sales

Profitability

EBT Margin

-551.20%

Return on Equity

-192.9%

Return on Assets

-148.52%

Fundamentals

Revenue

Revenue (TTM)

527.9M

Revenue Y/Y

-14.45%

Revenue Q/Q

-54.09%

Earnings

Earnings (TTM)

-3.5B

Earnings Y/Y

-556.7%

Earnings Q/Q

-0.03%

Price Action

52 Week Range

11.66
(Low)(High)

Last 30 days

-24.6%

Last 90 days

-20.7%

Trailing 12 Months

-80.5%

Financial Health

Current Ratio

11.84

Investor Care

Shares Dilution (1Y)

25.39%

Diluted EPS (TTM)

-2.71

Financials for Ginkgo Bioworks Holdings

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-2.1%528539438314197
Operating Expenses17.2%4,1873,5722,8842,142397
  S&GA Expenses93.0%1,66586335
  R&D Expenses12.5%1,8571,6501,4131,150226
Earnings Before Taxes-19.1%-3,538.15-2,971.68-2,407.82-1,838.12-250.00
Net Income-19.1%-3,529.04-2,961.87-2,399.80-1,830.05-202.88
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-6.2%1,8711,9942,0582,0712,151
  Current Assets-8.6%1,4621,5991,7061,7231,811
    Cash Equivalents-5.4%1,3031,3771,4931,5501,739
  Inventory-27.7%68933
  Net PPE6.4%188176149146143
  Goodwill-7.0%2931212117
Liabilities0.9%431427444504533
  Current Liabilities-7.6%12513515913590
Shareholder's Equity-6.2%1,4401,5351,5811,5051,552
  Retained Earnings-18.8%-4,226.31-3,557.25-2,888.43-2,297.93-697.27
  Additional Paid-In Capital11.2%5,6695,0984,4713,8052,250
Accumulated Depreciation6.7%8378706154
Shares Outstanding0.8%1,6211,6071,6111,487-
Minority Interest-84.2%532336266
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-8.0%-313.04-289.97-273.25-253.82-88.28
  Share Based Compensation19.7%3,4142,8512,2591,60615
Cashflow From Investing-20.8%-92.91-76.931,616-73.26-106.31
Cashflow From Financing-100.9%-13.641,535-194.431,5341,545
  Buy Backs-75.0%25100

Risks

What is the probability of a big loss on DNA?

62.4%


Probability that Ginkgo Bioworks Holdings stock will be more than 20% underwater in next one year

62.4%


Probability that Ginkgo Bioworks Holdings stock will be more than 30% underwater in next one year.

57.6%


Probability that Ginkgo Bioworks Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Ginkgo Bioworks Holdings was unfortunately bought at previous high price.

Returns

Cumulative Returns on DNA

Which funds bought or sold DNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
-
-
1,687
6,000
-%
2022-11-22
Capital Impact Advisors, LLC
NEW
-
118,000
118,000
0.12%
2022-11-22
IHT Wealth Management, LLC
-
-
50,000
161,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
2,856,000
2,856,000
0.03%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
584,000
2,632,000
-%
2022-11-18
Claro Advisors LLC
-
-
-
238,000
0.10%
2022-11-17
M&T Bank Corp
-
-
32,000
104,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
113.07
78,000
121,000
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
86,000
365,000
-%
2022-11-15
Coastal Bridge Advisors, LLC
UNCHANGED
-
103,000
434,000
0.12%

1–10 of 44

Latest Funds Activity

Are funds buying DNA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own DNA

Ginkgo Bioworks Holdings News

InvestorsObserver

Do Traders Think Ginkgo Bioworks Holdings Inc (DNA) Can Turn Around Friday?.26 hours ago

DNA Fair Value

Recent SEC filings of Ginkgo Bioworks Holdings

View All Filings
Date Filed Form Type Document
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 18, 2022
8-K
Current Report
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 18, 2022
4
Insider Trading
Nov 17, 2022
424B5
Prospectus Filed
Nov 16, 2022
4
Insider Trading
Nov 16, 2022
4
Insider Trading

Latest Insider Trading transactions for DNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-30
Canton Barry
SOLD
-184,098
1.793
-102,676
-
2022-11-30
Kelly Jason R
SOLD
-184,098
1.793
-102,676
See remarks
2022-11-30
Shetty Reshma P.
SOLD
-184,098
1.793
-102,676
See remarks
2022-11-29
Kelly Jason R
SOLD
-183,126
1.899
-96,433
See remarks
2022-11-29
Shetty Reshma P.
SOLD
-183,128
1.899
-96,434
See remarks
2022-11-29
Canton Barry
SOLD
-183,128
1.899
-96,434
-
2022-11-29
Shetty Reshma P.
SOLD
-183,126
1.899
-96,433
See remarks
2022-11-29
Canton Barry
SOLD
-183,126
1.899
-96,433
-

1–10 of 50

Jason Kelly
640
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

DNA Income Statement

2022-09-30
Condensed Consolidated Statement of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Biosecurity revenue:    
Total Revenue$ 66,398$ 77,610$ 379,421$ 165,343
Costs and operating expenses:    
In-process research and development259,58053,021871,488164,637
General and administrative expenses435,18428,9591,308,37981,326
Total operating expenses719,419104,2822,353,865309,075
Loss from operations(653,021)(26,672)(1,974,444)(143,732)
Other (expense) income:    
Interest income (expense), net5,820(528)7,097(1,481)
Loss on equity method investments(22,711)(39,651)(53,764)(72,621)
(Loss) gain on investments(1,758)(12,368)(39,981)3,009
Change in fair value of warrant liabilities(12,445)(18,482)96,099(18,482)
Gain on deconsolidation of subsidiaries15,989031,8890
Other (expense) income, net(957)(4,911)629863
Total other (expense) income, net(16,062)(75,940)41,969(88,712)
Loss before income taxes(669,083)(102,612)(1,932,475)(232,444)
Income tax benefit(28)(207)(257)(797)
Net Loss(669,055)(102,405)(1,932,218)(231,647)
Net loss attributable to non-controlling interest(0)(524)(3,833)(2,256)
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders$ (669,055)$ (101,881)$ (1,928,385)$ (229,391)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, basic$ (0.41)$ (0.08)$ (1.19)$ (0.18)
Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders, diluted$ (0.41)$ (0.08)$ (1.19)$ (0.18)
Weighted Average Number of Shares Outstanding, Basic1,630,910,6281,323,574,0631,619,790,3351,302,253,729
Weighted Average Number of Shares Outstanding, Diluted1,630,910,6281,323,574,0631,619,790,3351,302,253,729
Comprehensive loss:    
Net loss$ (669,055)$ (102,405)$ (1,932,218)$ (231,647)
Other comprehensive loss:    
Foreign currency translation adjustments(2,414)(877)(6,195)(877)
Total other Comprehensive Loss(2,414)(877)(6,195)(877)
Comprehensive loss(671,469)(103,282)(1,938,413)(232,524)
Product [Member]    
Biosecurity revenue:    
Total Revenue5,1908,49223,02414,622
Costs and operating expenses:    
Cost of Biosecurity revenue2,6603,43013,19915,185
Service [Member]    
Biosecurity revenue:    
Total Revenue36,52934,381265,98871,888
Costs and operating expenses:    
Cost of Biosecurity revenue21,99518,872160,79947,927
Foundry Revenue [Member]    
Biosecurity revenue:    
Total Revenue[1]$ 24,679$ 34,737$ 90,409$ 78,833
[1]Includes related party revenue of $10,032 and $13,124 for the three months ended September 30, 2022 and 2021, respectively, and $31,557 and $36,746 for the nine months ended September 30, 2022 and 2021, respectively.

DNA Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 1,302,603$ 1,550,004
Accounts receivable, net113,661131,544
Accounts receivable - related parties2,0954,598
Inventory, net5,8603,362
Prepaid expenses and other current assets ($6,500 and and $0 from related party)37,78433,537
Total current assets1,462,0031,723,045
Property and equipment, net187,577145,770
Investments96,310102,037
Equity method investments4,13513,194
Intangible assets, net47,93821,642
Goodwill28,80421,312
Other non-current assets43,92843,990
Total Assets1,870,6952,070,990
Current liabilities:  
Accounts payable11,3238,189
Deferred revenue ($8,518 and $12,502 from related parties)40,50533,240
Accrued expenses and other current liabilities72,99093,332
Total current liabilities124,818134,761
Non-current liabilities:  
Deferred rent, net of current portion21,00118,746
Deferred revenue, net of current portion ($137,577 and $148,319 from related parties)150,637155,991
Lease financing obligation59,84222,283
Warrant liabilities39,739135,838
Other non-current liabilities34,92235,992
Total Liabilities430,959503,611
Commitments and contingencies (Note 8)
Shareholders' equity:  
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued00
Common stock, $0.0001 par value (Note 6)165161
Additional paid-in capital5,668,7913,804,844
Accumulated deficit(4,226,310)(2,297,925)
Accumulated other comprehensive loss(7,910)(1,715)
Total Ginkgo Bioworks Holdings, Inc. stockholders equity1,434,7361,505,365
Non-controlling interest5,00062,014
Total stockholders equity1,439,7361,567,379
Total Liabilities and Shareholders' Equity$ 1,870,695$ 2,070,990